TALICIA HOLDINGS
PharmaTALICIA HOLDINGS is a pharmaceutical company focused on Infectious Disease. Key products include TALICIA.
TALICIA HOLDINGS's Key Drugs
TALICIA HOLDINGS's core commercial portfolio centers on TALICIA, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
TALICIA HOLDINGS's Recent FDA Approvals
New NDA/BLA approvals for TALICIA HOLDINGS over the last two years — novel drugs only, excluding generics and label supplements.
TALICIA HOLDINGS's Therapeutic Areas
TALICIA HOLDINGS's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TALICIA HOLDINGS's Top Competitors
TALICIA HOLDINGS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TALICIA HOLDINGS Pipeline Snapshot
Active clinical trials for TALICIA HOLDINGS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TALICIA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2019-11-01
- Latest
- 2024-05-01
- Applications
- 1